Neurospecific proteins and autoantibodies in serum of patients with acute ischemic stroke

Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova

Volumn 109, Issue 5, 2009, Pages 69-72

  Kamchatnov, P R ^a   Ruleva, N Yu ^a   Dugin, S F ^a   Buriachkovskaya, L I ^a   Chugunov, A V ^a   Mikhailova, N A ^a   Basse, D A ^a  

^a NONE

Author keywords

Acute ischemic stroke; Gliofibrillar acid protein; Neurospecific autoantibodies; Neurospecific enolase; S100 protein

Indexed keywords

ACID PROTEIN; AUTOANTIBODY; ENOLASE; GLIOFIBRILLAR ACID PROTEIN; NEUROSPECIFIC ENOLASE; PROTEIN S 100; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; HUMAN; NEUROLOGIC DISEASE; PROTEIN BLOOD LEVEL; RATING SCALE;

ACUTE DISEASE; ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; DISABILITY EVALUATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; RECOVERY OF FUNCTION; S100 PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 77953471078     PISSN: 00444588     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Anand N., Stead L. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc Dis 2005;20:213-219. (Pubitemid 41318197)
2. Foerch C., Curdt I., Yan B. et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg sychiat 2006;77:181-184 (Pubitemid 43220838)
3. Gao F., Harris D., Sapsed-Byrne S. Time course of Neurone-specific nolase and S100 rotein release during and after coronary artery bypass grafting. Br J Anaesth 1999;82:266-267. (Pubitemid 29057627)
4. Herrmann M., Vos P., Wunderlich M. et al. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S100B and glial fibrillary acidic protein. Stroke 2000;31:2670-2677. (Pubitemid 30813062)
5. Nylen K., Ost M., Csajbok L. et al. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 2006;240:85-91. (Pubitemid 41814959)
6. Petzold A., Michel P., Stock M., Schluep M. Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome. J Stroke Cerebrovasc Dis 2008;17:4:196-203. (Pubitemid 351853439)
7. Vos P., Lamers K., Hendriks J. et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004;62:8:1303-1309. (Pubitemid 38526041)
8. Pfeifer R., Borner A., Krack A. et al. Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron specific enolase and protein S100 and the Glasgow Coma Scale. Resuscitation 2005;65:49-55. (Pubitemid 40417455)
9. Jonsson H, Johnsson P., Backstrom M. et al. Controversial significance of early S100B levels after cardiac surgery. BMC Neurology 2004;4:24:2-18. (Pubitemid 40177006)
10. Huttunen H, Kuja-Panula J., Sorti G. et al. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000;275:40096-40105. (Pubitemid 32064635)
11. Lam A., Koppal T., Akama K et al. Mechanism of glial activation by S100B: involvement of the transcription factor NFB. Neurobiol Aging 2001;22:765-772. (Pubitemid 33055616)
12. Wilhelmsson U., Li L., Pekna M. et al. Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. J Neuroscience 2004;24:21:5016-5021. (Pubitemid 38697835)
13. Stein T., Fedynyshyn J., Kalil R. Circulating autoantibodies recognize and bind dying neurons following injury to the brain. J Neuropathol Exp Neurol 2002;61:12:1100-1108. (Pubitemid 35435029)
14. Kilmister S., Treasure T., McMillan T., Holt D. Neuropsychological change and S100 protein release in 130 unselected patients undergoing cardiac surgery. Stroke 1999;30:1869-1874. (Pubitemid 29411829)
15. Jönsson H., Johnsson P., Ailing C. et al. S100b after coronary artery bypass surgery: release pattern, source of contamination, and relation to neuropsychological outcome. Ann Thorac Surg 1999;68:2202-2208. (Pubitemid 30027850)
16. Kirkman N., Libbey J., Sweeten T et al. How relevant are GFAP autoantibodies in autism and Tourette Syndrome? J Autism Dev Disord 2008;38:2:333-341.
17. Toda Y., Matsuki K., Shibuya M. et al. Glial fibrillary acidic protein (GFAP) and anti-GFAP autoantibody in canine necrotising meningoencephalitis. Vet Rec 2007;161:8:261-264. (Pubitemid 47401188)
18. Scharfer B.W., Heizmann C.W. The S100 family of EF-hand calzium-binding proteins: function and pathology. Trends Biochem Sci 1996;21:134-140.
19. Zimmer D.B., Cornwall E.H., Landar A., Song W. The S100 family: history, function and expression. Brain Res Bull 1995;37:417-429.
20. Evans H. Markers of neurotoxicity: from behavior to autoantibodies against. Brain Proteins. Clin Chem 1995;41:12:1874-1881.
21. Shibuya M., Matsuki N., Fujiwara K. et al. Autoantibodies against glial fibrillary acidic protein (GFAP) in cerebrospinal fluids from Puf Dogs with necrotising meningoencephalitis. J Vet Med Sci 2007;69:3:241-245. (Pubitemid 46556868)